<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067441</url>
  </required_header>
  <id_info>
    <org_study_id>1002-050</org_study_id>
    <secondary_id>2016-004115-12</secondary_id>
    <nct_id>NCT03067441</nct_id>
  </id_info>
  <brief_title>Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)</brief_title>
  <official_title>A Multicenter Open-Label Extension (OLE) Study To Assess The Long-Term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 MG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Esperion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Esperion Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated
      in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately
      controlled by their current therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 3, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by MedDRA 18.1</measure>
    <time_frame>Baseline through Week 78</time_frame>
    <description>The primary outcome measure for this study is patient incidence of AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in Low-Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
    <description>Percent change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Low-Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
    <description>Change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 52 and 78</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in non-High-Density Lipoprotein Cholesterol (non-HDL-C)</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
    <description>Percent change from baseline in non-High-Density Lipoprotein Cholesterol (non-HDL-C) at Weeks 52 and 78</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Total Cholesterol</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
    <description>Percent change from baseline in Total Cholesterol at Weeks 52 and 78</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Apolipoprotein B (ApoB)</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
    <description>Percent change from baseline in Apolipoprotein B (ApoB) at Weeks 52 and 78</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in High-Sensitivity C-Reactive Protein (hs-CRP)</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
    <description>Percent change from baseline in High-Sensitivity C-Reactive Protein (hs-CRP) at Weeks 52 and 78</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Trigycerides</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
    <description>Percent change from baseline in Trigycerides at Weeks 52 and 78</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in High-Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>Baseline to Weeks 52 and 78</time_frame>
    <description>Percent change from baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 52 and 78</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1452</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Open-Label bempedoic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bempedoic acid 180 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bempedoic acid</intervention_name>
    <description>bempedoic acid 180 mg tablets taken orally, once per day.</description>
    <arm_group_label>Open-Label bempedoic acid</arm_group_label>
    <other_name>ETC-1002</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successfully completed CLEAR Harmony (1002-040) parent study

        Exclusion Criteria:

          -  Experienced a treatment-related SAE that led to study drug discontinuation in the
             CLEAR Harmony (1002-040) parent study.

          -  Medical condition requires lipid measurement and/or adjustment of background
             lipid-regulating therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Nash, MD</last_name>
    <role>Study Director</role>
    <affiliation>Esperion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jedidiah Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentral Clinical Research Services</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.esperion.com/company/contact-us/</url>
    <description>Contact Esperion</description>
  </link>
  <link>
    <url>http://www.who.int/mediacentre/factsheets/fs317/en/</url>
    <description>World Health Organization Fact Sheet No. 317</description>
  </link>
  <link>
    <url>http://thefhfoundation.org/about-fh/what-is-fh/</url>
    <description>Familial Hypercholesterolemia Foundation</description>
  </link>
  <link>
    <url>https://rarediseases.org/rare-diseases/familial-hypercholesterolemia/</url>
    <description>National Organization for Rare Disorders - Familial Hypercholesterolemia</description>
  </link>
  <reference>
    <citation>Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PH, Steinberg GR, Lalwani ND. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016 Nov 28;7:13457. doi: 10.1038/ncomms13457.</citation>
    <PMID>27892461</PMID>
  </reference>
  <reference>
    <citation>Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12. Erratum in: Circulation. 2015 Dec 22;132(25):e396. Circulation. 2014 Jun 24;129(25 Suppl 2):S46-8.</citation>
    <PMID>24222016</PMID>
  </reference>
  <reference>
    <citation>Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S1-8. doi: 10.1016/j.jacl.2011.04.003. Epub 2011 Apr 12.</citation>
    <PMID>21600525</PMID>
  </reference>
  <reference>
    <citation>Pollex RL, Joy TR, Hegele RA. Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81. doi: 10.1517/14728214.13.2.363 . Review.</citation>
    <PMID>18537526</PMID>
  </reference>
  <reference>
    <citation>Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 4;104(10):1108-13.</citation>
    <PMID>11535564</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperlipidemia</keyword>
  <keyword>cholesterol</keyword>
  <keyword>heterozygous familial hypercholesterolemia</keyword>
  <keyword>atherosclerotic cardiovascular disease</keyword>
  <keyword>ASCVD</keyword>
  <keyword>HeFH</keyword>
  <keyword>LDL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

